EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain

Thursday, April 09, 2020
EicOsis Logo

DAVIS, Calif., April 9, 2020 /PRNewswire/ -- EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of the soluble Epoxide Hydrolase (sEH) enzyme, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to its lead drug candidate, EC5026, for the treatment of neuropathic pain. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application. Read more here.

Was this page helpful?
Form Approved OMB# 0925-0648 Exp. Date 05/31/2021